GlassScriptPhysician profile
Colby Koenig
NPI 1659914919
$5,093.60
in general payments reported to CMS, 2019-2025
30 companies · $2,081 in 2025
The $2,081 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $483 · 2022: $375 · 2023: $565 · 2024: $1,590 · 2025: $2,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,910 · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,909.80 |
| Education | $325.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,039.70 | 2021-2025 | |
| Ucb, INC. | $534.90 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $380.03 | 2022-2025 | Sotyktu, Eliquis |
| Genzyme Corporation | $365.70 | 2024-2025 | |
| Abbvie INC. | $318.16 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $270.95 | 2021-2023 | Verquvo |
| Medtronic, INC. | $264.82 | 2021-2023 | Cobalt Dr Mri Surescan |
| Sun Pharmaceutical Industries INC. | $231.77 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $222.15 | 2021-2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $220.48 | 2024-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $139.73 | 2024-2025 | Adbry |
| Dermavant Sciences, INC. | $124.84 | 2024 | Vtama |
| Amgen INC. | $120.61 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $117.71 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $104.85 | 2024 | Tremfya |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Galderma Laboratories, L.P. | $94.22 | 2025 | Nemluvio |
| Janssen Pharmaceuticals, INC | $81.54 | 2021-2022 | |
| Incyte Corporation | $59.95 | 2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $55.79 | 2025 | Zoryve |
| Daiichi Sankyo INC. | $51.74 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.97 | 2021-2023 | Jardiance |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.18 | 2024-2025 | Cabtreo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.04 | 2021-2023 | Lifevest |
| Vital Connect, INC | $26.18 | 2023 | Vitalpatch Rtm |
| Journey Medical Corporation | $20.19 | 2025 | |
| Tactile Systems Technology INC | $13.34 | 2021 | |
| Amarin Pharma, INC. | $12.76 | 2021 | |
| Biofrontera INC. | $12.47 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Mayne Pharma Commercial LLC | $5.84 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colby Koenig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.